The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
Ace J. Hatch
No relevant relationships to disclose
Herbert Pang
No relevant relationships to disclose
Mark D. Starr
No relevant relationships to disclose
John C. Brady
No relevant relationships to disclose
Jingquan Jia
No relevant relationships to disclose
Donna Niedzwiecki
No relevant relationships to disclose
Alan Paul Venook
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Stephanie M. Cushman
No relevant relationships to disclose
Herbert Hurwitz
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Regeneron; Roche; Sanofi
Research Funding - Amgen; Genentech; GlaxoSmithKline; Morphotek; Roche; Sanofi ; TRACON Pharma
Andrew B. Nixon
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Research Funding - Amgen; Pfizer; Roche; TRACON Pharma